IX BIOPHARMA LTD

Discover how iX Biopharma’s innovative sublingual wafers, from ketamine pain relief to erectile dysfunction treatment, are reshaping health care in Singapore, Australia, and Malaysia.

iX Biopharma pushes its sublingual ketamine wafer toward U.S. FDA EUA, targeting battlefield pain relief and early military adoption.

iX Biopharma’s Wafermine hits a pivotal FDA EUA milestone, opening U.S. battlefield pain relief and early revenue while phase‑3 trials continue.

Singapore’s iX Biopharma pioneers sublingual pain & ED treatments like Wafermine and BnoX, blending pharma, nutraceuticals and lab services for global health impact.

Discover iX Biopharma’s breakthrough sublingual ketamine and buprenorphine wafer therapies for acute pain, plus nutraceuticals and lab services driving growth in Singapore and beyond.

Discover iX Biopharma Ltd.—Singapore’s innovative pharmaceutical and nutraceutical pioneer developing sublingual ketamine wafers for pain relief and more.

Explore iX Biopharma’s journey from pioneering pain‑management wafers like Wafermine to nutraceuticals, amid market volatility and a challenging P/E ratio.

iX Biopharma Ltd. explores breakthrough pain‑management wafers in Singapore and beyond, balancing cutting‑edge innovation with volatile financial performance.